{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:42Z","timestamp":1785132102651,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leptomeningeal metastases (LM) from melanoma are rare and associated with dismal outcomes. Intrathecal PD-1 antibody therapy has shown encouraging activity in LM. Radiotherapy may enhance tumor immunogenicity and potentially augment immune checkpoint blockade within the central nervous system. The efficacy and safety of combining intrathecal PD-1 antibodies with whole-brain radiotherapy (WBRT) in melanoma LM remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed melanoma patients with LM who received intrathecal PD-1 antibody therapy between June 2022 and December 2024. Patients were categorized according to whether WBRT was administered within 30 days of intrathecal PD-1 antibody therapy: intrathecal monotherapy and combination therapy. Overall survival (OS) and intracranial progression-free survival (iPFS) were descriptively evaluated by treatment exposure, with between-group analyses considered exploratory and hypothesis-generating. Adverse events were graded using CTCAE v5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>20 patients were included, of whom 7 received intrathecal PD-1 antibody monotherapy and 13 received intrathecal PD-1 antibody therapy combined with WBRT. The observed median OS was 20.1 weeks (95% CI, 13.3-not reached) in the intrathecal monotherapy group and 45.3 weeks (95% CI, 28.7-not reached) in the combination group. The observed median iPFS was 10.0 weeks (95% CI, 6.1-not reached) and 23.0 weeks (95% CI, 18.4-not reached), respectively. Treatment-related adverse events were manageable, and no new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intrathecal PD-1 antibody therapy combined with WBRT showed numerically longer OS and iPFS than intrathecal therapy alone in this small retrospective descriptive series of melanoma leptomeningeal metastasis. These hypothesis-generating findings warrant prospective investigation but do not establish comparative efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1830452","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:37Z","timestamp":1785130837000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of intrathecal anti-PD-1 therapy with or without whole-brain radiotherapy in melanoma leptomeningeal metastasis: a multicenter retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Junjie","family":"Zhen","sequence":"first","affiliation":[{"name":"Department of Oncology, Guangdong Sanjiu Brain Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongcheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Department of Biological Therapy Center, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Department of Biological Therapy Center, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Ding","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Department of Biological Therapy Center, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Wen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Department of Biological Therapy Center, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangdong Sanjiu Brain Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangdong Sanjiu Brain Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangdong Sanjiu Brain Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Department of Biological Therapy Center, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linbo","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangdong Sanjiu Brain Hospital","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Department of Biological Therapy Center, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000507","article-title":"How we treat patients with leptomeningeal metastases","volume":"4","author":"Le Rhun","year":"2019","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061884","article-title":"Leptomeningeal disease (LMD) in patients with melanoma metastases","volume":"15","author":"Khaled","year":"2023","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-12-265","article-title":"Leptomeningeal metastases from a primary central nervous system melanoma: a case report and literature review","volume":"12","author":"Pan","year":"2014","journal-title":"World J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-803508-5.00019-6","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from Malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01155-3","article-title":"Systemic therapy for melanoma brain and leptomeningeal metastases","volume":"24","author":"Sherman","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01261-4","article-title":"Leptomeningeal metastases: New opportunities in the modern era","volume":"19","author":"Wilcox","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1472945","article-title":"A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04843-8","article-title":"Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence","volume":"170","author":"Zhen","year":"2024","journal-title":"J Neuro-Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081792","article-title":"Radiotherapy and systemic treatment for leptomeningeal disease","volume":"12","author":"Frechette","year":"2024","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00641","article-title":"Palliative radiotherapy for leptomeningeal carcinomatosis-analysis of outcome, prognostic factors, and symptom response","volume":"8","author":"El Shafie","year":"2019","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis--the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J Neuro-Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6488-4","article-title":"Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab","volume":"259","author":"Bot","year":"2012","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0b013e32835e589c","article-title":"Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report","volume":"23","author":"Lee","year":"2013","journal-title":"Melanoma Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","article-title":"Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)","volume":"142","author":"Ferguson","year":"2019","journal-title":"J Neuro-Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejca.2021.02.016","article-title":"Leptomeningeal disease from melanoma-poor prognosis despite new therapeutic modalities","volume":"148","author":"Chorti","year":"2021","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now183","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae103","article-title":"Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions","volume":"26","author":"Wilcox","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12771","article-title":"Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities","volume":"32","author":"Eroglu","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0004","article-title":"Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient","volume":"12","author":"Wu","year":"2020","journal-title":"Immunotherapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36959\/885\/364","article-title":"Clinical response of central nervous system melanoma to anti-PD1 therapy in 2 melanoma patients","volume":"1","author":"Glitza","year":"2023","journal-title":"Arch Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40263-022-00975-5","article-title":"Leveraging molecular and immune-based therapies in leptomeningeal metastases","volume":"37","author":"Wilcox","year":"2023","journal-title":"CNS Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.11.012","article-title":"Management of leptomeningeal metastases: prognostic factors and associated outcomes","volume":"27","author":"Brower","year":"2016","journal-title":"J Clin Neurosci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01668-z","article-title":"Utility of whole brain radiation therapy for leptomeningeal carcinomatosis","volume":"25","author":"Hirano","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638873","article-title":"Optimizing the treatment schedule of radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy in metastatic cancers","volume":"11","author":"Kong","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fonc.2016.00212","article-title":"Combining radiation therapy with immune checkpoint blockade for central nervous system Malignancies","volume":"6","author":"D'Souza","year":"2016","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12964-023-01139-8","article-title":"Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations","volume":"21","author":"Wu","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13046-025-03281-2","article-title":"Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects","volume":"44","author":"Rafiq","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf183","article-title":"Phase IB study of avelumab and whole brain radiotherapy (WBRT) in patients with leptomeningeal disease (LMD) from solid tumors: results and molecular analyses","volume":"27","author":"Pi\u00f1a","year":"2025","journal-title":"Neuro Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1830452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:38Z","timestamp":1785130838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1830452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1830452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1830452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1830452"}}